Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Angelika Daehling"'
Autor:
Sebastian Ochsenreither, Jose Manuel Trigo Perez, Jürgen Krauss, Lucie Heinzerling, Thomas Eigentler, Franz-Georg Bauernfeind, Marc Oliva, Peter Mohr, Angelika Daehling, Patrick Terheyden, Carsten Weishaupt, Beate Schmitt-Bormann, Juan Martin-Liberal, Oliver Schönborn-Kellenberger, Ulrike Gnad-Vogt, Sarah-Katharina Kays, Céleste Lebbé, Tobias Seibel, Michael Fluck, Claudia Stosnach, Peter Brossart
Publikováno v:
Late-breaking abstracts.
Background CV8102 is a non-coding, non-capped RNA complexed with a carrier peptide activating the innate (via TLR7/8, RIG-I) and adaptive immune system.1 2 An ongoing phase I trial is investigating i.t. CV8102 either as a single agent or in combinati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2317fe2ee168f0caed902daba8faa5be
https://doi.org/10.1136/jitc-2020-sitc2020.0800
https://doi.org/10.1136/jitc-2020-sitc2020.0800
Autor:
Sarah-Katharina Kays, Tobias Seibel, Thomas Eigentler, Claudia Stosnach, Fatma Funkner, Regina Heidenreich, Peter Mohr, Birgit Scheel, Juergen Krauss, Ulrike Gnad-Vogt, Juergen C. Becker, Felix Kiecker, Ralf Gutzmer, Oliver Schoenborn-Kellenberger, Lucie Heinzerling, Angelika Daehling, Jutta Sylvina Schreiber, Benjamin Weide, Patrick Terheyden, Tanja Strack, Carsten Weishaupt, Ute Klinkhardt
Publikováno v:
Cancer Research. 79:LB-021
CV8102 comprises a single-stranded non-coding RNA complexed with a cationic peptide. It acts as an agonist to TLR-7/-8 and RIG-I (Ziegler 2018) to stimulate the innate and adaptive immune system. CV8102 was shown to induce an upregulation of inflamma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::934d52a2360323ef6cedde5744909dfc
https://doi.org/10.1158/1538-7445.am2019-lb-021
https://doi.org/10.1158/1538-7445.am2019-lb-021
Autor:
Patrick Baumhof, Tilmann Roos, Angelika Daehling, Karl-Josef Kallen, Regina Heidenreich, Birgit Scheel, Henoch S. Hong, Aleksandra Kowalczyk, Karl Melber, Mariola Fotin-Mleczek, Söhnke Voss, Keyvan Tadjalli Mehr, Sven D. Koch, Ulrike Gnad-Vogt, Johannes Lutz, Janine Noth
Publikováno v:
Journal for Immunotherapy of Cancer
Meeting abstracts Purified recombinant proteins and peptides, which are currently under development in various anti-cancer vaccination approaches, lack sufficient immunogenicity. Therefore, potent adjuvants are needed to induce strong and persistent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c861f2e62319dc2d4d8417d86e1a81f
https://doi.org/10.1186/2051-1426-3-s2-p163
https://doi.org/10.1186/2051-1426-3-s2-p163
Autor:
Benjamin Weide, Lucie Heinzerling, Patrick Terheyden, Jürgen Krauss, Jutta Sylvina Schreiber, Peter Brossart, Peter Mohr, Franz G Bauernfeind, Michael Fluck, Carsten Weishaupt, Angelika Daehling, Claudia Stosnach, Jürgen C. Becker, Thomas Eigentler, Gianluca Quintini, Sebastian Ochsenreither, Sarah-Katharina Kays, Fatma Funkner, Anke Muth, Senta Ulrike Gnad-Vogt
Publikováno v:
Web of Science
3096 Background: CV8102 is a non-coding, non-capped RNA that activates the innate (via TLR7/8, RIG-I) and adaptive immunity dose-dependently. CV8102 injected intratumorally (i.t.), as a single agent or combined with systemic anti-PD-1 antibody (Ab) l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee3f0367afb1e567ebe1fb8082f3824e
https://publons.com/wos-op/publon/34619263/
https://publons.com/wos-op/publon/34619263/
